FDA officials are advising pharmacists and patients to disregard recent news stories that they say "have created misperceptions about the effectiveness of newergeneration hormonal contraceptives."
According to the FDA, "the stories inaccurately report that the products are significantly less effective at preventing pregnancy than those approved decades ago." In truth, agency officials said, the newer-generation products are "highly effective."
The stories mistakenly suggested that the agency called a meeting to discuss the need for higher standards of efficacy for the newer products.
In reality, FDA officials said, the purpose of the meeting was "to discuss clinical trial designs that reflect the diversity of users of hormonal contraceptives, expectations for efficacy and safety, and user acceptability of the newer-generation products, including cycle control."
Get to know RESPIMAT, the slow-moving mist inhaler from Boehringer Ingelheim Pharmaceuticals, Inc.
Watch the RESPIMAT video and test your knowledge with a short multiple-choice quiz. When you get all the answers right, you’ll receive a certificate naming you a RESPIMAT T.O.P. Performer. Why not check it out today?
Clinical features with downloadable PDFs